SVB Wealth LLC Acquires 209 Shares of Illumina, Inc. (NASDAQ:ILMN)

SVB Wealth LLC lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,277 shares of the life sciences company’s stock after purchasing an additional 209 shares during the period. SVB Wealth LLC’s holdings in Illumina were worth $450,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ILMN. Bamco Inc. NY increased its stake in shares of Illumina by 1.5% in the 1st quarter. Bamco Inc. NY now owns 272,364 shares of the life sciences company’s stock valued at $37,401,000 after acquiring an additional 4,023 shares in the last quarter. GUARDCAP ASSET MANAGEMENT Ltd increased its stake in Illumina by 1.1% in the first quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 2,068,869 shares of the life sciences company’s stock valued at $284,097,000 after purchasing an additional 22,067 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of Illumina during the 1st quarter worth about $6,026,000. Guardian Capital Advisors LP acquired a new stake in shares of Illumina in the 1st quarter valued at about $1,237,000. Finally, Canada Pension Plan Investment Board increased its position in Illumina by 154.9% in the 1st quarter. Canada Pension Plan Investment Board now owns 279,351 shares of the life sciences company’s stock valued at $38,360,000 after buying an additional 169,756 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ILMN has been the subject of several research reports. TD Cowen reduced their price target on shares of Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a research report on Thursday, June 6th. Royal Bank of Canada decreased their target price on shares of Illumina from $249.00 to $242.00 and set an “outperform” rating for the company in a research report on Monday, July 1st. Evercore ISI dropped their price target on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 11th. Barclays boosted their price objective on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Finally, Robert W. Baird raised their target price on Illumina from $125.00 to $128.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average price target of $158.57.

Illumina Stock Performance

Shares of Illumina stock traded down $0.17 during trading hours on Tuesday, reaching $121.39. The company had a trading volume of 215,082 shares, compared to its average volume of 2,112,024. The firm has a market cap of $19.34 billion, a PE ratio of -14.92 and a beta of 1.15. Illumina, Inc. has a one year low of $89.00 and a one year high of $195.64. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The business has a fifty day simple moving average of $110.13 and a 200 day simple moving average of $123.94.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm’s revenue was down 1.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.08 EPS. On average, analysts anticipate that Illumina, Inc. will post 1.38 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.